Peptide Library

Human study PLS-00186

Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.primary · Urologic oncology · 2010-09-22 · PMID 20864366 · DOI

Design and participants

Design
Other design
Population
Tissue samples from clinical patients (normal bladder, urothelial carcinoma pTa and pT3, paracancerous tissue) plus two bladder cancer cell lines
Conditions
Urothelial (transitional cell) carcinoma of the bladder
Setting
Union Hospital of Tongji Medical College (China)
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (publication type). No funder is named.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Tβ4 likely plays a crucial role in EMT progression in bladder cancer. Inhibiting its expression, or its interactions with other genes, may be a novel therapeutic target for highly invasive and metastatic bladder cancers.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Mechanistic tissue-expression and cell-line work in which no person received thymosin β4, so it gives no clinical evidence on administration.
    • abstract only: Only the abstract is available. Sample sizes per group and quantitative results are not reported.
    • inappropriate population: Study examined endogenous Tβ4 expression in bladder tumour tissue and cell lines. No participants received Tβ4 and no clinical outcomes were measured.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 20864366, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 20864366, abstract (Materials and methods, sentences 1-4) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 20864366, abstract (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 20864366, abstract (Materials and methods, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).